• N Schlegel, S Flemming, M Meir, and C-T Germer.
• Klinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie, AG Inflammation und Sepsis, Universitätsklinik Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Deutschland, Schlegel_N@ukw.de.
• Chirurg. 2014 Aug 1;85(8):714-9.

AbstractSepsis remains a critical problem in virtually all fields of clinical medicine. Despite intensive scientific and clinical efforts no significant progress has emerged in the fight against sepsis mortality. Solely the algorithm of the "surviving sepsis campaign" has proven to result in significantly enhanced survival of sepsis patients when consequently adopted. Novel research in the field of the complex immunological alterations in sepsis suggests that ongoing immunosuppression is the critical determinant underlying sepsis mortality. Therefore, it was proposed that immunostimulation might be a successful approach to improve outcome in individually selected patients. Others favor a different view on the pathophysiology of sepsis and support the notion that the manifestation of organ failure may be the dominant therapeutic target. Due to the fact that breakdown of the microcirculation and disruption of the microvascular barrier are critical events preceding organ failure, experimental therapeutic efforts to address these events led to promising results. Taken together, in view of the many initially promising experimental data and the failure to translate them into successful clinical therapies, a different view on the pathophysiology of sepsis is warranted to obtain the key for novel therapeutic options.

32 keywords...

hide…